Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Market Closed 07-10 16:00:00 EDT

5.81

-0.30

-4.91%

盘后5.85

+0.04+0.69%

19:58 EDT

High6.12	Low5.81	Vol6.09M
Open6.10	D1 Closing6.11	Amplitude5.07%
Mkt Cap2.02B	Tradable Cap1.48B	Total Shares347.60M
T/O35.99M	T/O Rate2.39%	Tradable Shares255.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":5.81,"timestamp":1783713600000,"preClose":6.11,"halted":0,"volume":6087984,"hourTrading":{"tag":"盘后","latestPrice":5.85,"preClose":5.81,"latestTime":"19:58 EDT","volume":86899,"amount":505010.2204,"timestamp":1783727932446,"change":0.04,"changeRate":0.006885,"amplitude":0.012048},"delay":0,"changeRate":-0.049099836333879,"floatShares":254999999,"shares":347597289,"eps":-0.424745,"marketStatus":"Market Closed","change":-0.3,"latestTime":"07-10 16:00:00 EDT","open":6.1,"high":6.12,"low":5.81,"amount":35989793.182224,"amplitude":0.050736,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.424745,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":6.11,"preHourTrading":{"tag":"盘前","latestPrice":6.17,"preClose":6.11,"latestTime":"09:28 EDT","volume":6758,"amount":41513.934456,"timestamp":1783690084443,"change":0.06,"changeRate":0.00982,"amplitude":0.00982},"postHourTrading":{"tag":"盘后","latestPrice":5.85,"preClose":5.81,"latestTime":"19:58 EDT","volume":86899,"amount":505010.2204,"timestamp":1783727932446,"change":0.04,"changeRate":0.006885,"amplitude":0.012048},"volumeRatio":0.792987,"impliedVol":1.2497,"impliedVolPercentile":0.5936},"requestUrl":"/m/hq/s/NUVB/tweets","defaultTab":"tweets","newsList":[{"id":"2649980357","title":"Nuvation Bio is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980357","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980357?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:36","pubTimestamp":1783427760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings(END) Dow Jones NewswiresJuly 07, 2026 08:36 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649267104","title":"Nuvation Bio Prices Upsized USD 287.5 Million Convertible Senior Notes After Full Greenshoe Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2649267104","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649267104?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:10","pubTimestamp":1783372239,"startTime":"0","endTime":"0","summary":"Nuvation Bio prices upsized USD 287.5 million convertible senior notes after full greenshoe exerciseNuvation Bio priced USD 287.5 million of 0.75% Convertible Senior Notes due 2032 following full exer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL9pdR1K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649671052","title":"Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2649671052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649671052?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:10","pubTimestamp":1783372214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5MJCKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648056730","title":"Nuvation Bio Plans Offering of $200 Million Convertible Senior Notes Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2648056730","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648056730?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:18","pubTimestamp":1782854281,"startTime":"0","endTime":"0","summary":"Nuvation Bio plans offering of $200 million convertible senior notes due 2032Nuvation Bio launched an underwritten offering of USD 200 million Convertible Senior Notes due 2032.Underwriters received a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9CDRbw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648569313","title":"Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2648569313","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648569313?lang=en_us&edition=fundamental","pubTime":"2026-07-01 03:08","pubTimestamp":1782846488,"startTime":"0","endTime":"0","summary":"Nuvation Bio's  Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a \"more durable, frontline-driven growth profile,\" with investors eyeing revenue variability, Wedbush said in a note Tuesday.The brokerage said it expects quarterly revenue to become \"materially more predictable\" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an \"underappreciated long-term value driver.\"The firm reiterated its outperform rating on the stock with $11 price target.Price: 5.74, Change: +0.13, Percent Change: +2.23","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647712783","title":"Nuvation Bio's Taletrectinib Enters UK Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2647712783","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647712783?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:37","pubTimestamp":1782736639,"startTime":"0","endTime":"0","summary":"Nuvation Bio  said Monday that the UK Medicines and Healthcare products Regulatory Agency has validated the marketing authorization application for taletrectinib, moving it into formal regulatory review.The drug targets ROS1-positive non-small cell lung cancer, the company said.The filing is supported by phase 2 TRUST-I and TRUST-II trial data, the company said.Taletrectinib is already approved in the US, China, and Japan, it added.Nuvation Bio stock rose 1.5% in Monday's premarket.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647237966","title":"Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-positive Non-small Cell Lung Cancer Validated in the United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2647237966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647237966?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:00","pubTimestamp":1782734409,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA6NZRQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646311139","title":"Nuvation Bio (NUVB) Completes $250 Million Note Offering, Is The Stock Fully Priced?","url":"https://stock-news.laohu8.com/highlight/detail?id=2646311139","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646311139?lang=en_us&edition=fundamental","pubTime":"2026-06-28 11:20","pubTimestamp":1782616830,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) recently completed a $250 million offering of 0.75% convertible senior notes due 2032, drawing investor attention as the company refines its capital structure and funds its oncology development pipeline.\nSee our latest analysis for Nuvation Bio.\nNuvation Bio’s share price has risen 39.51% over the past 90 days and 18.20% over the past 30 days, while its 1 year total shareholder return of 192.75% contrasts with a year to date share price decline of 34.15%. This suggests...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-completes-250-million-note-offering-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-completes-250-million-note-offering-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646350922","title":"Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2646350922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646350922?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:11","pubTimestamp":1782479461,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7%, and the actively traded Invesco QQQ Trust (QQQ) retreated 1.6% in Friday's premarket activity, as investors shifted th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VDC","XLI","EETH","HIVE","SLV","UNG","XLK","XLP",".DJI","IYJ","QQQ","AER.AU","GLD","NUVB","IYK","SPY","EQNR","EQR","SOXX","BETH","XLF","IYE","IYW","VIS","FAZ","AER","IPK","FDN","IYH","USO","VHT.AU","XLE","IGM","TCOM","VHT","IVV","IWM","FAS","IBB","RTH.AU","XLV","XLY","SPY.AU","ISBC","BITO","XRT","MSFT","XSD","RTH","EXI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646835106","title":"Nuvation Bio prices upsized offering of $250M of convertible senior notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646835106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646835106?lang=en_us&edition=fundamental","pubTime":"2026-06-26 19:20","pubTimestamp":1782472842,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) “announced the pricing of its underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior No...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-prices-upsized-offering-of-250m-of-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-prices-upsized-offering-of-250m-of-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646335506","title":"Nuvation Bio Announces Pricing of Upsized Offering of $250.0 Million of Convertible Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646335506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646335506?lang=en_us&edition=fundamental","pubTime":"2026-06-26 11:59","pubTimestamp":1782446356,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nTUA5FRXM2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646806736","title":"Nuvation Bio Slides on Planned $200 Mln Convertible Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2646806736","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646806736?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:16","pubTimestamp":1782396981,"startTime":"0","endTime":"0","summary":"BUZZ-Nuvation Bio slides on planned $200 mln convertible offering** Cancer treatment firm Nuvation Bio'sNUVB.Nshares down 7.1% to $6 and threatening to snap 5-day winning streak on Thurs as it seeks capital raise** NUVB announces public offering of $200 mln convertible bonds due 2032** Co intends to use net offering proceeds to fully repay loan agreement, and for general purposes, including working capital, opex and capex** Also expects to use some proceeds to pay cost of capped call transactions to mitigate potential dilution** Jefferies, Citigroup and Cantor Fitzgerald joint bookrunners, joined by RBC** New York City-based NUVB has roughly $2 bln market cap** With the decline, stock down 33% YTD** Avg rating of 11 analysts is \"buy\"; median PT $12, per LSEG data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nL6N42X0XV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1244550494.USD","LU2462157665.USD","BK4559","JEF","BK4588","LU2236285917.USD","LU0170899867.USD","LU2456880835.USD","LU0162691827.USD","BK4566","BK4007","LU1244550577.SGD","LU2125154778.USD","LU0320765646.SGD","LU1267930227.SGD","LU0477156953.USD","LU2125154935.USD","LU0980610538.SGD","LU2360032135.SGD","LU0203347892.USD","LU0310800965.SGD","BK4534","NUVB","LU0128525689.USD","LU0648001328.SGD","LU1162221912.USD","IE00BSNM7G36.USD","LU1791807156.HKD","LU0106831901.USD","LU0314106906.USD","LU1201861249.SGD","LU0098860793.USD","LU1244550221.USD","LU0052756011.USD","LU1366192091.USD","BK4207","LU0203345920.USD","LU1506573853.SGD","LU1668664300.SGD","BK4127","LU0072461881.USD","LU0130517989.USD","LU2417539215.USD","LU0130102774.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809837","title":"Nuvation Bio falls -10.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646809837?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:05","pubTimestamp":1782396338,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is down -10.1%, or -65c to $5.81. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-10-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-10-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646855872","title":"Nuvation Bio Plans USD 200 Million Convertible Senior Notes Offering Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2646855872","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646855872?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:02","pubTimestamp":1782385323,"startTime":"0","endTime":"0","summary":"Nuvation Bio plans USD 200 million convertible senior notes offering due 2032Nuvation Bio launched a proposed offering of USD 200 million convertible senior notes due 2032.Deal includes a 30-day optio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL6D8BJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874705","title":"Nuvation Bio - to Offer $200 Mln Convertible Senior Notes Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874705?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA43XRNV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874030","title":"Nuvation Bio - Proceeds to Fund Capped Calls, Repay Senior Loan, and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874030","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874030?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA43XRNV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646844102","title":"Nuvation Bio CFO Philippe Sauvage Disposes of 47,668 Common Shares Worth $286,650.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2646844102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646844102?lang=en_us&edition=fundamental","pubTime":"2026-06-25 07:07","pubTimestamp":1782342467,"startTime":"0","endTime":"0","summary":"Nuvation Bio CFO Philippe Sauvage disposes of 47,668 common shares worth $286,650.16Nuvation Bio CFO Philippe Sauvage exercised stock options for 47,668 Class A shares at $2.17 on June 23.He sold 47,6","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL75phNV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nuvation Bio CFO Philippe Sauvage Disposes of 47,668 Common Shares Worth $286,650.16","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644649167","title":"Nuvation Bio posts corporate deck spotlighting IBTROZI launch, oncology pipeline programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2644649167","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644649167?lang=en_us&edition=fundamental","pubTime":"2026-06-17 02:12","pubTimestamp":1781633556,"startTime":"0","endTime":"0","summary":"Nuvation Bio highlighted IBTROZI  as a commercial-stage growth driver in advanced ROS1+ NSCLC, with U.S., Japan, China clearances.U.S. net product revenue reached USD 24.7 million in 2025; quarterly revenue rose to USD 18.5 million in Q1 2026.More than 600 new patient starts were recorded through March 31, 2026; over 50% of new starts were first-line in Q1 2026.Cash, cash equivalents, and marketable securities totaled USD 533.7 million as of March 31, 2026; management expects a path to profitability without additional funding.Pipeline focus includes pivotal SIGMA study enrollment for safusidenib in IDH1-mutant glioma; preclinical Drug-Drug Conjugate candidates remain under evaluation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuva","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL7WH6P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642623079","title":"Nuvation Bio director Robert Mashal reports purchase of 25,000 shares for $118,250","url":"https://stock-news.laohu8.com/highlight/detail?id=2642623079","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642623079?lang=en_us&edition=fundamental","pubTime":"2026-06-12 08:03","pubTimestamp":1781222608,"startTime":"0","endTime":"0","summary":"Nuvation Bio director Robert Mashal reported an indirect purchase of 25,000 Class A common shares at USD 4.73.Indirect holdings rose to 225,000 shares, held through a trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL4BNCrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nuvation Bio director Robert Mashal reports purchase of 25,000 shares for $118,250","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423125","title":"Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Teva Pharmaceutical (TEVA) and Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423125?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:41","pubTimestamp":1781091672,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merit Medical Systems (MMSI), Teva Pharmaceutical (T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merit-medical-systems-mmsi-teva-pharmaceutical-teva-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merit-medical-systems-mmsi-teva-pharmaceutical-teva-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBI","LU1983299246.USD","BK4198","LU0566484027.USD","BK4557","LU2324357040.USD","LABU","HCSG","BK4584","BK4566","BK4588","BK4007","BK4559","LU0128526141.USD","LU1559883803.SGD","BK4581","BK4137","BK4596","XLV","LU0029874061.USD","TEVA","NUVB","MMSI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0193},{"period":"1month","weight":0.2686},{"period":"3month","weight":0.263},{"period":"6month","weight":-0.2774},{"period":"1year","weight":1.5152},{"period":"ytd","weight":-0.3516}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.099824},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.044723},{"month":3,"riseRate":0.5,"avgChangeRate":0.083814},{"month":4,"riseRate":0.5,"avgChangeRate":0.010626},{"month":5,"riseRate":0.666667,"avgChangeRate":0.014611},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044383},{"month":7,"riseRate":0.666667,"avgChangeRate":0.058742},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}